1. Home
  2. NAMS vs SHOO Comparison

NAMS vs SHOO Comparison

Compare NAMS & SHOO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NAMS
  • SHOO
  • Stock Information
  • Founded
  • NAMS 2019
  • SHOO 1990
  • Country
  • NAMS Netherlands
  • SHOO United States
  • Employees
  • NAMS N/A
  • SHOO N/A
  • Industry
  • NAMS Biotechnology: Pharmaceutical Preparations
  • SHOO Shoe Manufacturing
  • Sector
  • NAMS Health Care
  • SHOO Consumer Discretionary
  • Exchange
  • NAMS Nasdaq
  • SHOO Nasdaq
  • Market Cap
  • NAMS 2.5B
  • SHOO 1.7B
  • IPO Year
  • NAMS N/A
  • SHOO 1993
  • Fundamental
  • Price
  • NAMS $21.54
  • SHOO $25.48
  • Analyst Decision
  • NAMS Strong Buy
  • SHOO Hold
  • Analyst Count
  • NAMS 8
  • SHOO 6
  • Target Price
  • NAMS $42.88
  • SHOO $26.00
  • AVG Volume (30 Days)
  • NAMS 946.1K
  • SHOO 1.3M
  • Earning Date
  • NAMS 08-06-2025
  • SHOO 07-30-2025
  • Dividend Yield
  • NAMS N/A
  • SHOO 3.29%
  • EPS Growth
  • NAMS N/A
  • SHOO N/A
  • EPS
  • NAMS N/A
  • SHOO 2.32
  • Revenue
  • NAMS $47,140,000.00
  • SHOO $2,284,080,000.00
  • Revenue This Year
  • NAMS N/A
  • SHOO $12.44
  • Revenue Next Year
  • NAMS N/A
  • SHOO $8.22
  • P/E Ratio
  • NAMS N/A
  • SHOO $11.02
  • Revenue Growth
  • NAMS 586.97
  • SHOO 10.34
  • 52 Week Low
  • NAMS $14.06
  • SHOO $19.05
  • 52 Week High
  • NAMS $27.29
  • SHOO $50.01
  • Technical
  • Relative Strength Index (RSI)
  • NAMS 64.18
  • SHOO 54.32
  • Support Level
  • NAMS $17.97
  • SHOO $24.84
  • Resistance Level
  • NAMS $22.15
  • SHOO $26.54
  • Average True Range (ATR)
  • NAMS 0.92
  • SHOO 1.00
  • MACD
  • NAMS 0.35
  • SHOO 0.15
  • Stochastic Oscillator
  • NAMS 86.50
  • SHOO 72.18

About NAMS NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

About SHOO Steven Madden Ltd.

Steven Madden Ltd designs and sells brand-name and private-label footwear and accessories. Its products are geared toward fashion-conscious adults and children. The company sells its products through department stores and other retailers as well as its stores and websites. The company's revenue comes from its operating segments: Wholesale Footwear, Wholesale Accessories or Apparel, Direct-to-Consumer, and Licensing. The wholesale footwear segment accounts for the majority of revenue.

Share on Social Networks: